Karen Blindauer

Summary

Affiliation: Medical College of Wisconsin
Country: USA

Publications

  1. ncbi request reprint A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
    Karen Blindauer
    Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
    Arch Neurol 63:210-6. 2006
  2. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
  3. ncbi request reprint Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
  4. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
  5. ncbi request reprint Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial
    Andrew Siderowf
    Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 17:758-63. 2002
  6. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
  7. doi request reprint Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008

Collaborators

Detail Information

Publications7

  1. ncbi request reprint A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations
    Karen Blindauer
    Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
    Arch Neurol 63:210-6. 2006
    ..Etilevodopa is an ethyl-ester prodrug of levodopa that has greater gastric solubility, passes quickly into the small intestine, is rapidly hydrolyzed to levodopa, and has a shortened time to maximum levodopa concentration...
  2. ncbi request reprint Rasagiline improves quality of life in patients with early Parkinson's disease
    Kevin M Biglan
    Department of Neurology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    Mov Disord 21:616-23. 2006
    ..Rasagiline improved QOL compared with placebo. This QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagiline...
  3. ncbi request reprint Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  4. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  5. ncbi request reprint Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial
    Andrew Siderowf
    Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Mov Disord 17:758-63. 2002
    ..The findings are in agreement with previous reports on interrater reliability...
  6. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  7. doi request reprint Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease
    William B White
    Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center and Clinical Trials Unit, University of Connecticut, Farmington, Connecticut 06030 3940, USA
    Hypertension 52:587-93. 2008
    ..3%, 2.6%, and 2.9% of the placebo, 0.5-mg, and 1.0-mg rasagiline groups, respectively. These data demonstrate that rasagiline did not induce postprandial hypertension in patients with Parkinson disease who were on an unrestricted diet...